KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash from Financing Activities (2016 - 2025)

Evolent Health (EVH) has 11 years of Cash from Financing Activities data on record, last reported at -$93.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 195.97% year-over-year to -$93.0 million; the TTM value through Dec 2025 reached -$35.9 million, down 6258.23%, while the annual FY2025 figure was -$35.9 million, 6258.23% down from the prior year.
  • Cash from Financing Activities reached -$93.0 million in Q4 2025 per EVH's latest filing, down from -$41.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $379.7 million in Q1 2023 and bottomed at -$103.4 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $17.3 million, with a median of -$9.0 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: soared 26901.72% in 2022, then tumbled 677.15% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $60.9 million in 2021, then tumbled by 117.82% to -$10.9 million in 2022, then crashed by 677.15% to -$84.4 million in 2023, then skyrocketed by 214.93% to $96.9 million in 2024, then plummeted by 195.97% to -$93.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$93.0 million in Q4 2025, -$41.8 million in Q3 2025, and -$8.9 million in Q2 2025.